CYTK Cytokinetics Inc stock chart & analysis
Conviction 46HealthcareScan · Fri, Nov 6, 2026Cytokinetics Inc (CYTK) closed at $53.69 (-3.35%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 27, RS Rating 22, -39.1% from its 52-week high, -15.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
CYTK technical analysis
Trend
CYTK is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 18.2% below the 50-day ($65.68) and 23.2% below the 200-day ($69.97). ADX(14) at 25 points to a moderate trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 27, in oversold territory. MACD crossed below its signal line one session ago. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 22 puts its weighted 12-month performance ahead of about 22% of the US market.
Volume and volatility
Volume on the latest session ran 1.8× its 20-day average. It trades about $112.9M a day on average. ATR(14) is $2.73, 5.1% of price — its typical daily range. A Bollinger Band squeeze just fired. On-balance volume is trending down. Chaikin Money Flow (-0.34) shows distribution.
Key levels
The chart pattern's support is $59.97 and its resistance $66.42. The 52-week range is $53.57 to $88.31; price is 39.1% below the high and 0.3% above the low. The VWAP anchored at the 52-week high is $71.67, above price.
Performance
CYTK returned -14.7% (1 week), -13.3% (1 month), -30.6% (3 months), -30.1% (6 months), -9.2% (1 year), -15.4% (year to date).
About Cytokinetics Inc
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Pharmaceutical Preparations · Listed 2004 · 673 employees
Recent news
- CYTOKINETICS INC: Earnings resultsSEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in CYTK · 5 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-09-29 | Buy | $1K–$15K | 2026-09-29 | 2026-10-12 | |
Gilbert Cisneros house · D · CA · traded 2026-06-30 | Buy | $1K–$15K | 2026-06-30 | 2026-07-02 | |
Gilbert Cisneros house · CA · traded 2025-10-09 | Buy | $1K–$15K | 2025-10-09 | 2025-11-12 | |
 Lisa McClain house · R · MI · traded 2025-06-17 | Sell | $1K–$15K | 2025-06-17 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-11 | Buy | $1K–$15K | 2025-06-11 | 2025-08-13 |
Insider activity
SEC Form 4 transactions in CYTK · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Malik Fady Ibraham EVP Research & Development · Common Stock · 2026-11-03 | Sell | 3.5K | $220K | 2026-11-03 | 2026-11-03 |
Malik Fady Ibraham EVP Research & Development · Non-Qualified Stock Option (Right to Buy) · 2026-11-03 | Exercise | 3.5K | — | 2026-11-03 | 2026-11-03 |
Malik Fady Ibraham EVP Research & Development · Common Stock · 2026-11-03 | Exercise | 3.5K | $27K | 2026-11-03 | 2026-11-03 |
Blum Robert I President & CEO · Non-Qualified Stock Option (Right to Buy) · 2026-11-02 | Exercise | 7.5K | — | 2026-11-02 | 2026-11-02 |
Blum Robert I President & CEO · Common Stock · 2026-11-02 | Exercise | 7.5K | $80K | 2026-11-02 | 2026-11-02 |
Blum Robert I President & CEO · Common Stock · 2026-11-02 | Sell | 7.5K | $471K | 2026-11-02 | 2026-11-02 |
Blum Robert I President & CEO · Common Stock · 2026-09-15 | Sell | 97.93K | $6.8M | 2026-09-15 | 2026-09-15 |
Landry Robert E Director · Common Stock · 2026-09-15 | Sell | 1K | $72K | 2026-09-15 | 2026-09-15 |
Blum Robert I President & CEO · Common Stock · 2026-09-14 | Gift | 1.35K | — | 2026-09-14 | 2026-09-15 |
Blum Robert I President & CEO · Common Stock · 2026-09-14 | Exercise | 7.5K | $80K | 2026-09-14 | 2026-09-15 |
SEC filings
EDGAR filings in CYTK · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.